Blauvelt, Andrew, Howard Sofen, Jo Lambert, Joseph F. Merola, Mark Lebwohl, Kim Hoyt, Subhashis Banerjee, Thomas Scharnitz, and Jeffrey J. Crowley. “Efficacy of Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Scalp Psoriasis by Baseline Psoriasis Area and Severity Index (PASI) and Baseline Body Surface Area (BSA): A Subanalysis of the Phase 3 Clinical Trial Data”. SKIN The Journal of Cutaneous Medicine 8, no. 4 (July 23, 2024): s405. Accessed July 23, 2024. https://jofskin.org/index.php/skin/article/view/2855.